Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study.

Authors
Category Primary study
Conference2026 ASCO Annual Meeting
Year 2026
This article has no abstract
Epistemonikos ID: 117f0b5c942afc692522847166abc45b8c75eca4
First added on: Jul 04, 2026